



Synthesis, Pharmacological Characterization, and Structure–Activity Relationship Studies of Small Molecular Agonists for the Orphan GPR88 Receptor

Chunyang Jin,^{*,†} Ann M. Decker,[†] Xi-Ping Huang,[‡] Brian P. Gilmour,[†] Bruce E. Blough,[†] Bryan L. Roth,[‡] Yang Hu,[§] Joseph B. Gill,[§] and X. Peter Zhang[§]

[†]Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States


[‡]National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States

[§]Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States

Supporting Information

ABSTRACT: GPR88 is an orphan G-protein-coupled receptor (GPCR) enriched in the striatum. Genetic deletion and gene expression studies have suggested that GPR88 plays an important role in the regulation of striatal functions and is implicated in psychiatric disorders. The signal transduction pathway and receptor functions of GPR88, however, are still largely unknown due to the lack of endogenous and synthetic ligands. In this paper, we report the synthesis of a GPR88 agonist 2-PCCA and its pure diastereomers, which were functionally characterized in both transiently and stably expressing GPR88 HEK293 cells. 2-PCCA inhibited isoproterenol-stimulated cAMP accumulation in a concentration-dependent manner in cells expressing GPR88 but not in the control cells, suggesting that the observed cAMP inhibition is mediated through GPR88 and that GPR88 is coupled to G_{α_i} . 2-PCCA did not induce calcium mobilization in GPR88 cells, indicating no G_{α_q} -mediated response. A structure–activity relationship (SAR) study of 2-PCCA was also conducted to explore the key structural features for GPR88 agonist activity.

KEYWORDS: Orphan GPR88, agonists, 2-PCCA



GPR88 is an orphan G-protein-coupled receptor, which was originally identified as a striatum-specific receptor (designated Strg/GPR88),¹ though it is also expressed in other brain regions, including the cerebral cortex, amygdala, and hypothalamus.² In the striatum, GPR88 is highly expressed in both D₁ and D₂ receptor-expressing medium spiny neurons (MSNs),^{2b,3} suggesting the receptor may play a role in regulating dopaminergic activity. GPR88 knockout mice demonstrated disrupted prepulse inhibition of the startle response, a phenotype of schizophrenia, and exhibited D₂ receptors hypersensitivity (as evidenced by increased sensitivity to apomorphine-induced climbing and stereotypy, and amphetamine-stimulated locomotor activity).⁴ In another study of GPR88 knockout mice,^{3,5} the animals exhibited increased locomotion, and impaired motor coordination and cue-based learning. GPR88 re-expression normalized these impaired behaviors, suggesting that GPR88 dysfunction may contribute to abnormal behaviors observed in neurological and psychiatric diseases.³ In line with these findings from GPR88 knockout studies, transcriptional profiling studies have revealed GPR88 gene expression is altered by treatment or conditions related to schizophrenia,⁶ bipolar disorder,⁷ depression,⁸ and drug addiction.⁹ Taken together, these studies suggest that GPR88 plays an important role in the regulation of striatal functions

and is a promising drug target for treating basal ganglia-associated disorders.

In order to elucidate the biological function of GPR88, selective agonists are required. Recently, a series of surrogate agonists of GPR88 have been reported in the patent literature and were suggested to activate GPR88 coupling to G_{α_i} pathways.¹⁰ However, the function and structure–activity relationship (SAR) relative to these compounds are unclear. In this paper, we report the synthesis of a GPR88 ligand 2-PCCA [(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarboxylic acid ((2S,3S)-2-amino-3-methylpentyl)-(4'-propylbiphenyl-4-yl)-amide (1); Figure 1] and its pure (1R,2R)- and (1S,2S)-diastereomers (2 and 3, respectively), which were functionally characterized in the GPR88 cell-based cAMP assays. A series of 2-PCCA analogues (4a–i, 5a–e, 6a, and 6b; Figure 2) were also synthesized and examined to explore the SAR of this chemical scaffold at GPR88.

Received: April 14, 2014

Revised: May 2, 2014

Published: May 2, 2014




Figure 1. Structures of 2-PCCA (1), 2, and 3.




Figure 2. 2-PCCA analogues.


CHEMISTRY

2-PCCA (1) and the 4-substituted bisphenyl analogues 4a–i were synthesized by a known procedure,^{10b} outlined in Scheme 1, with some modifications. A diastereomeric mixture was first synthesized to characterize the GPR88 signaling pathways. Asymmetric synthesis of both pure diastereomers 2 and 3 of 2-PCCA was conducted later to determine which isomer is more active. Cyclopropanation of 2-vinylpyridine (8) with *tert*-butyl diazoacetate under catalytic conditions led to *tert*-butyl ester 9, which was then treated with 4 M HCl in dioxane to give the racemic (1*R**,2*R**)-2-(pyridin-2-yl)cyclopropanecarboxylic acid (10) in 56% yield. Reductive amination of aldehyde 12, prepared by Dess–Martin oxidation of commercially available (–)-(2*S*,3*S*)-*N*-Boc-2-amino-3-methyl-1-pentanol with 4-bromoaniline (11) afforded amine 13 in 75% yield. With both building blocks available, amide 14 was synthesized in 72% yield by converting acid 10 into the corresponding acid chloride, followed by reaction with amine 13. Suzuki coupling of 14 with an appropriate arylboronic acid under microwave conditions gave intermediates 15a–j in the range of 65–96% yields. Removal of the Boc protecting group with 4 M HCl in dioxane provided 1 and 4a–i in 90–98% yields. Compounds 1 and 4a–i were determined to be 1:1 diastereomeric mixtures by ¹H NMR and HPLC analyses.

Synthesis of pure diastereomers 2 and 3 of 2-PCCA is described in Scheme 2. The key intermediate 14, prepared from enantiomerically pure (–)-(2*S*,3*S*)-*N*-Boc-2-amino-3-methyl-1-pentanol as described in Scheme 1, is a 1:1 mixture of (1*R*,2*R*)- and (1*S*,2*S*)-diastereomers differentiating at the configuration of the *trans*-substituted cyclopropane ring. Asymmetric syn-

thesis of (1*R*,2*R*)-14 was accomplished starting from the preparation of pure enantiomer (1*R*,2*R*)-2-(pyridin-2-yl)-cyclopropanecarboxylic acid ((1*R*,2*R*)-10). Thus, asymmetric cyclopropanation of 8 using the known chiral porphyrin catalyst [Co(3,5-Di^{*t*}Bu-ChenPhyrin)]¹¹ afforded the *tert*-butyl ester (1*R*,2*R*)-9 in 97% ee, as determined by chiral HPLC analysis. The chiral porphyrin Co(II) catalysts have been well studied in the asymmetric cyclopropanation of olefins using diazoacetates to give the corresponding cyclopropanes with high diastereoselectivity and enantioselectivity.¹¹ Assignment of the absolute configuration of (1*R*,2*R*)-9 was made based on an analogy to the known (1*R*,2*R*)-2-phenyl-1-cyclopropanecarboxylic acid *tert*-butyl ester^{11a} synthesized using the same chiral porphyrin catalyst. Acidic hydrolysis of (1*R*,2*R*)-9 led to acid (1*R*,2*R*)-10, which was then coupled with amine 13 to provide (1*R*,2*R*)-14 in 40% yield over three steps. To obtain the pure diastereomer (1*S*,2*S*)-14, the mixture 14 was separated by HPLC using a ChiralPak IA column to afford (1*R*,2*R*)-14 and (1*S*,2*S*)-14 in 40% and 39% yield, respectively. Suzuki coupling of (1*R*,2*R*)-14 and (1*S*,2*S*)-14 with 4-propylphenylboronic acid, followed by removal of the Boc protecting group with HCl gave 2 and 3, in 80% and 81% yield, respectively.

Compounds 5a–e were synthesized using the procedure, outlined in Scheme 3, analogous to that used to prepare 1. Reductive amination of an appropriate aldehyde 17a–e with 4-bromoaniline (11) or 4-(4'-propylphenyl)aniline (16) afforded amine 18a–e in 50–86% yields. Amide formation with the acid chloride, prepared from the racemic 10, gave 19a–e in 53–60% yields. Suzuki coupling of 19a, 19b, and 19e with 4-propylphenylboronic acid yielded 53–80% of 20a, 20b, and

Scheme 1^a

^aReagents: (a) *tert*-butyl diazoacetate, 5,10,15,20-tetraphenyl-21*H*,23*H*-porphine cobalt(II), toluene, 80 °C, 2 h; (b) 4 M HCl/dioxane, DCM, rt, overnight; (c) NaBH(OAc)₃, 1,2-dichloroethane, rt, overnight; (d) 10/oxalyl chloride/DCM/40 °C/2 h, concentrated, then 13/Et₃N/DCM, rt, overnight; (e) arylboronic acid, Pd(dppf)Cl₂·DCM, K₃PO₄, DME/H₂O (3:1), microwave, 160 °C, 6 min; (f) 4 M HCl/dioxane, DCM, rt, 6 h.

20e. Deprotection of the Boc group furnished **5a–e** as 1:1 diastereomeric mixtures in 92–98% yields.


Synthesis of compounds **6a** and **6b** started with the reaction of amine **13** with (1*R*,2*R*)-2-phenyl-1-cyclopropanecarboxylic acid¹² and 2-pyridylacetic acid (Scheme 4), respectively. The resulting amides **21a** and **21b** were coupled with 4-propylphenylboronic acid, followed by HCl treatment to provide **6a** and **6b** in 55% and 33% overall yield, respectively. All synthesized compounds has >95% pure as determined by HPLC analyses. The ¹H NMR spectra of the target compounds were in agreement with the assigned structures.

RESULTS AND DISCUSSION


Despite emerging pharmacological implications of the orphan GPR88 receptor, little is known regarding its downstream signaling pathways, as identification of endogenous and synthetic ligands has been elusive. Results from the patent literature¹⁰ indicated that GPR88 couples to Gα_i proteins and thereby inhibits cAMP production. To develop an appropriate cell based assay system to support drug discovery for the GPR88 receptor, we initially transiently cotransfected HEK 293T cells with the human GPR88 cDNA and a luminescent cAMP biosensor and determined both Gα_s and Gα_i activations.¹³ 2-PCCA (**1**) produced no measurable increases in cAMP levels at concentrations up to 30 μM. As a positive control, isoproterenol (ISO) activated the endogenous β₂ adrenergic receptors expressed in HEK293T cells and greatly stimulated cAMP production in a concentration-dependent

manner. 2-PCCA inhibited ISO-induced cAMP formation with a pEC₅₀ value of 6.06 (EC₅₀ = 877 nM) in GPR88 cells but not in the control cells transiently transfected with the biosensor, demonstrating that 2-PCCA activates GPR88-mediated Gα_i signaling (Figure 3). In addition, the (1*R*,2*R*)-isomer **2** (EC₅₀ = 373 nM) is approximately 5-fold more potent than the (1*S*, 2*S*)-isomer **3**. Furthermore, 2-PCCA did not induce calcium mobilization measured by the fluorescent imaging plate reader (FLIPR) calcium assay^{13b,14} in HEK293T/GPR88 cells (data not shown), indicating that GPR88 is likely not coupled to Gα_q proteins in our assay systems.

To further characterize the GPR88 in vitro functions and explore the key structural features of 2-PCCA agonist activity, HEK293 cells stably expressing the human GPR88 receptor and the GloSensor-22F cAMP construct were established. In the stable GPR88-22F cells, 2-PCCA and its pure diastereomer **2** had pEC₅₀ values of 6.04 (EC₅₀ = 911 nM) and 6.22 (EC₅₀ = 603 nM), respectively. To explore the SAR of 2-PCCA, substitution effects of the bisphenyl moiety were first examined. As seen in Table 1, unsubstituted analogue **4a** was less potent than 2-PCCA. The 4-position tolerated small to medium size of alkyl substitutions with the methyl analogue **4b** (EC₅₀ = 845 nM) and cyclohexyl analogue **4e** (EC₅₀ = 746 nM) being the most potent compounds in the series. Replacing the methyl group with an electron-withdrawing trifluoromethyl group (**4f**) markedly reduced activity. The addition of a fluoro or chloro group to the 4-position led to **4g** and **4h**, respectively, resulting in even lower potency. Somewhat surprisingly, the 4-acetyl

Scheme 2^a

^aReagents: (a) *tert*-butyl diazoacetate, 1 mol % Co(3,5-di-*t*-Bu-ChenPhyrin) catalyst, DMAP, toluene, rt, 48 h; (b) 4 M HCl/dioxane, DCM, rt, overnight; (c) (1*R*, 2*R*)-**10**/oxalyl chloride/DCM/40 °C/2 h, concentrated, then **13**/Et₃N/DCM, rt, overnight; (d) HPLC separation; (e) 4-propylphenylboronic acid, Pd(dppf)Cl₂·DCM, K₃PO₄, DME/H₂O (3:1), microwave, 160 °C, 6 min; (f) 4 M HCl/dioxane, DCM, rt, 6 h.


Scheme 3^a

^aReagents: (a) NaBH(OAc)₃, 1,2-dichloroethane, rt, overnight; (b) **10**/oxalyl chloride/DCM/40 °C/2 h, concentrated, then **18a–e**/Et₃N/DCM, rt, overnight; (c) 4-propylphenylboronic acid, Pd(dppf)Cl₂·DCM, K₃PO₄, DME/H₂O (3:1), microwave, 160 °C, 6 min; (d) 4 M HCl/dioxane, DCM, rt, 6 h.

analogue **4i** possessed a similar potency (EC₅₀ = 923 nM) at GPR88 relative to 2-PCCA.

Investigation of the substituted ethylamine moiety of 2-PCCA (Table 2) showed that hydrophobic substitutions were well tolerated. The trend of increased potency with large

substituents (**5a–e**) at the ethylamine moiety suggests that a hydrophobic pocket may be present in the GPR88 receptor. A limited examination of the amide carbonyl groups observed that the pyridyl group in 2-PCCA could be replaced with a phenyl group (**6a**) while causing only a slight decrease in potency.

Scheme 4^a

^aReagents: (a) **21a**: (1*R*, 2*R*)-2-phenyl-1-cyclopropanecarboxylic acid/ SOCl_2 /reflux, overnight, concentrated, then **13**/ Et_3N /DCM, rt, overnight; **21b**: 2-pyridylacetic acid, HBTU, Et_3N , MeCN, rt, overnight; (b) 4-propylphenylboronic acid, $\text{Pd}(\text{dppf})\text{Cl}_2\cdot\text{DCM}$, K_3PO_4 , DME/ H_2O (3:1), microwave, 160 °C, 6 min; (c) 4 M HCl/dioxane, DCM, rt, 6 h.




Figure 3. HEK 293T cells were transiently transfected with GPR88 and GloSensor cAMP construct (A) or GloSensor cAMP only (B). 2-PCCA (**1**), **2**, and **3** inhibited isoproterenol-induced cAMP production in GPR88 cells, but not in the control cells. The data are the means of quadruplicate measurements with standard deviation shown as error bars and are representative of at least three independent experiments.


However, replacement of the cyclopropane moiety with a methylene group (**6b**) resulted in a loss of activity, indicating the central linker of the aromatic and carbonyl moieties is critical for GPR88 recognition.

CONCLUSIONS

In summary, we demonstrated that GPR88 couples to the $\text{G}\alpha_i$ subunits, and is activated by 2-PCCA in both transient and stable GPR88 expressing cells. In an effort to determine the key structural features for 2-PCCA agonist activity, we designed and synthesized a series of 2-PCCA analogues **4a–i**, **5a–e**, **6a**, and **6b**. Further pharmacological evaluation of the (1*R*,2*R*)-isomer **2** and phenyl analogue **6a**, including receptor specificity and in vivo behavioral studies, are in progress. These studies will facilitate the identification of highly potent, selective ligands for GPR88 and the understanding of its physiological functions in vivo.


METHODS

Chemistry. General Methods. Melting points were determined using a MEL-TEMP II capillary melting point apparatus and are uncorrected. Nuclear magnetic resonance (^1H NMR and ^{13}C NMR) spectra were obtained on a Bruker Avance DPX-300 MHz NMR spectrometer. Chemical shifts are reported in parts per million (ppm) with reference to internal solvent. ^{13}C NMR data of diastereomeric mixtures were not reported due to the complexity of the spectra. Mass spectra (MS) were run on a PerkinElmer Sciex API 150 EX mass spectrometer. HRMS spectra were run on a Waters Synapt G2 HDMS Q-TOF mass spectrometer, using electrospray ionization in positive ion mode. Optical rotations were measured on an AutoPol III polarimeter, purchased from Rudolf Research. Analytical thin-layer chromatography (TLC) was carried out using EMD silica gel 60 F_{254} TLC plates. TLC visualization was achieved with a UV lamp or in an iodine chamber. Flash column chromatography was done on a CombiFlash Companion system using Isco prepac silica gel columns. Unless otherwise stated, reagent-grade chemicals were obtained from commercial sources and were used without further purification. All moisture- and air-sensitive reactions and reagent transfers were carried out under dry nitrogen.

Table 1. Structures and Activities of Compounds 1, 2, and 4a–i**1, 4a–i** **(R, R)* and *(S, S)* mixture
2 **(R, R)*-isomer

compd ^a	R	pEC ₅₀ (EC ₅₀ , nM) ^b
2-PCCA (1)	Pr	6.04 ± 0.06 (911)
2	Pr	6.22 ± 0.10 (603)
4a	H	5.48 ± 0.08 (3321)
4b	Me	6.07 ± 0.14 (845)
4c	Et	5.70 ± 0.08 (1989)
4d	<i>i</i> -Bu	5.74 ± 0.06 (1803)
4e	cyclohexyl	6.13 ± 0.13 (746)
4f	CF ₃	5.49 ± 0.08 (3266)
4g	fluoro	NA ^c
4h	chloro	NA ^c
4i	acetyl	6.03 ± 0.05 (923)

^aAll compounds were tested as the HCl salt. ^bpEC₅₀ values are means ± standard error of at least three independent experiments performed in duplicate. ^cEC₅₀ > 10 μM, tested in two independent experiments performed in duplicate.

Table 2. Structures and Activities of Compounds 5a–e, 6a, and 6b**5a–e**
(R, R)* and *(S, S)* mixture6a, b**

compd ^a	R ¹	R ²	pEC ₅₀ (EC ₅₀ , nM) ^b
2-PCCA (1)			6.04 ± 0.06 (911)
5a	H		5.27 ± 0.12 (5330)
5b	Me		5.42 ± 0.12 (3821)
5c	<i>i</i> -Pr		5.80 ± 0.09 (1602)
5d	<i>i</i> -Bu		6.00 ± 0.21 (994)
5e	PhCH ₂		6.05 ± 0.19 (898)
6a	(1 <i>R</i> ,2 <i>R</i>)-2-phenyl-cyclopropan-1-yl		5.90 ± 0.05 (1250)
6b	(pyridin-2-yl)methyl		NA ^c

^aAll compounds were tested as the HCl salt. ^bpEC₅₀ values are means ± standard error of at least three independent experiments performed in duplicate. ^cEC₅₀ > 10 μM

(±)-*tert*-Butyl (1*R**,2*R**)-2-(pyridin-2-yl)cyclopropanecarboxylate (**9**). A solution of 2-vinylpyridine (**8**) (0.58 mL, 5.4 mmol), *tert*-butyl diazoacetate (0.88 mL, 6.4 mmol), and 5,10,15,20-tetraphenyl-21*H*,23*H*-porphine cobalt(II) (72 mg, 0.11 mmol) in toluene (25 mL) was heated in a sealed tube at 80 °C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–30% EtOAc in hexanes afforded **9** (0.82 g, 69%) as a

brown oil: ¹H NMR (300 MHz; CDCl₃) δ 8.44 (d, *J* = 6.0 Hz, 1H), 7.56 (td, *J* = 6.0, 3.0 Hz, 1H), 7.23 (t, *J* = 6.0 Hz, 1H), 7.11–6.93 (m, 1H), 2.51 (ddd, *J* = 9.0, 6.0, 3.0 Hz, 1H), 2.16 (ddd, *J* = 9.0, 6.0, 3.0 Hz, 1H), 1.57–1.48 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz; CDCl₃) δ 172.6, 159.3, 149.4, 135.9, 123.3, 121.1, 80.5, 28.2, 26.8, 25.4, 17.2; MS (ESI) *m/z* 220.4 [*M* + *H*]⁺.

(±)-*tert*-Butyl (1*R**,2*R**)-2-(pyridin-2-yl)cyclopropanecarboxylic Acid Hydrochloride (**10**). To a solution of **9** (0.80 g, 3.65 mmol) in CH₂Cl₂ (10 mL) was added 4 M HCl in dioxane (3 mL), and the reaction was stirred at room temperature overnight. The solvent was removed under reduced pressure. The residue was triturated with CH₂Cl₂/Et₂O to afford **10** (0.60 g, 81%) as a greenish solid: mp 141–143 °C; ¹H NMR (300 MHz; DMSO-*d*₆) δ 12.00 (br s, 1H), 8.67 (dd, *J* = 6.0, 3.0 Hz, 1H), 8.30 (td, *J* = 6.0, 3.0 Hz, 1H), 7.81–7.68 (m, 2H), 2.90 (ddd, *J* = 9.0, 6.0, 3.0 Hz, 1H), 2.33 (ddd, *J* = 9.0, 6.0, 3.0 Hz, 1H), 1.80–1.60 (m, 2H); ¹³C NMR (75 MHz; DMSO-*d*₆) δ 172.5, 156.1, 134.5, 143.0, 123.8, 123.4, 25.0, 23.2, 17.3; MS (ESI) *m/z* 164.4 [*M* + *H*]⁺.

tert-Butyl [(2*S*,3*S*)-1-[(4-Bromophenyl)amino]-3-methylpentan-2-yl]carbamate (**13**). To a solution of (–)-(2*S*,3*S*)-*N*-Boc-2-amino-3-methyl-1-pentanol (2.17 g, 10.0 mmol) in water-saturated CH₂Cl₂ (10 mL) at room temperature was added Dess-Martin reagent (8.90 g, 21.0 mmol), and the reaction was stirred for 1 h. Additional water-saturated CH₂Cl₂ (5 mL) was added every 15 min during the reaction time. The mixture was diluted with Et₂O (100 mL) and poured into a solution of Na₂S₂O₃ (17 g) in 80% saturated NaHCO₃ (100 mL). After stirring for 10 min, the layers were separated and the aqueous layer was extracted with Et₂O (100 mL). The combined organic layers were washed with ice-cold saturated NaHCO₃ (30 mL) and water (30 mL). The solution was dried (Na₂SO₄) and concentrated under reduced pressure to give the crude aldehyde **12**. To a solution of 4-bromoaniline (**11**) (1.72 g, 10.0 mmol) in dichloroethane (60 mL) was added the above crude aldehyde, followed by NaBH(OAc)₃ (4.24 g, 20.0 mmol). The mixture was stirred at room temperature overnight. Saturated NaHCO₃ (20 mL) was added, and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–30% EtOAc in hexanes afforded **13** (2.78 g, 75%) as a white solid: mp 103–105 °C; [*α*]_D²³ +11.4° (c 0.52, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 7.24 (d, *J* = 9.0 Hz, 2H), 6.45 (d, *J* = 9.0 Hz, 2H), 4.52 (d, *J* = 9.0 Hz, 1H), 4.20 (br s, 1H), 3.82–3.65 (m, 1H), 3.30–3.14 (m, 1H), 3.05–2.89 (m, 1H), 1.60–1.47 (m, 1H), 1.44 (s, 9H), 1.23–1.10 (m, 1H), 0.95 (d, *J* = 6.0 Hz, 3H), 0.95 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 154.9, 145.7, 130.1, 112.4, 106.9, 77.9, 52.9, 45.0, 35.7, 26.6, 23.6, 13.8, 9.9; MS (ESI) *m/z* 371.3 [*M* + *H*]⁺ (⁷⁹Br), 373.3 [*M* + *H*]⁺ (⁸¹Br).

tert-Butyl [(2*S*,3*S*)-1-[(4-Bromophenyl)-[(1*R**,2*R**)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino]-3-methylpentan-2-yl]carbamate (**14**). To a solution of **10** (0.40 g, 2.0 mmol) in CH₂Cl₂ (20 mL) at room temperature was added oxalyl chloride (0.35 mL, 4.0 mmol) and DMF (50 μL). The mixture was stirred at 40 °C for 2 h and then cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (20 mL) and treated with **13** (0.74 g, 2.0 mmol) and Et₃N (1.1 mL, 8.0 mmol). The resulting solution was stirred at room temperature overnight. Saturated NaHCO₃ (10 mL) was added, and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layers were washed with brine (3 × 20 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–25% EtOAc in hexanes afforded **14** (0.74 g, 72%, 1:1 diastereomeric mixture) as a light yellow foam: ¹H NMR (300 MHz; CDCl₃) δ 8.30 (d, *J* = 6.0 Hz, 1H), 7.58–7.34 (m, 3H), 7.22–6.98 (m, 4H), 4.96 (d, *J* = 9.0 Hz, 1H), 4.45–4.25 (m, 1H), 3.80–3.78 (m, 1H), 3.21–3.06 (m, 1H), 2.71–2.62 (m, 0.5 H), 2.58–2.48 (m, 0.5 H), 1.98–1.86 (m, 1H), 1.75–1.62 (m, 1H), 1.60–1.35 (m, 3H), 1.45 and 1.40 (2s, 9H), 1.15–1.02 (m, 1H), 0.92–0.80 (m, 6H); MS (ESI) *m/z* 516.7 [*M* + *H*]⁺ (⁷⁹Br), 518.6 [*M* + *H*]⁺ (⁸¹Br).

tert-Butyl [(2S,3S)-1-((4'-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15a). A mixture of **14** (0.48 g, 0.92 mmol), 4-propylphenylboronic acid (0.25 g, 1.4 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (70 mg, 0.092 mmol), and K₃PO₄ (0.58 g, 2.7 mmol) in dimethoxyethane (10.5 mL) and water (3.5 mL) was heated in a sealed vessel by microwave irradiation at 160 °C for 6 min. The resulting mixture was poured into 1 N NaOH solution (30 mL) and extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–20% EtOAc in hexanes afforded **15a** (0.49 g, 96%, 1:1 diastereomeric mixture) as a white foam: ¹H NMR (300 MHz; CDCl₃) δ 8.28–8.22 (m, 1H), 7.58–7.38 (m, 5H), 7.32–7.13 (m, 5H), 7.03–6.96 (m, 1H), 5.12–5.05 (m, 1H), 4.48–4.36 (m, 1H), 3.85–3.56 (m, 1H), 3.24–3.13 (m, 1H), 2.71–2.50 (m, 3H), 2.05–1.95 (m, 1H), 1.75–1.58 (m, 3H), 1.51–1.38 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.56–1.40 (m, 1H), 0.97 (t, J = 7.5 Hz, 3H), 0.92–0.80 (m, 6H); MS (ESI) *m/z* 557.0 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((Biphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15b). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 11 mg (0.087 mmol) of phenylboronic acid to give 24 mg (81%) of **15b** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.28–8.22 (m, 1H), 7.59–7.38 (m, 6H), 7.37–7.14 (m, 5H), 7.12–6.95 (m, 1H), 5.14–5.07 (m, 1H), 4.49–4.36 (m, 1H), 3.85–3.68 (m, 1H), 3.26–3.14 (m, 1H), 2.75–2.66 (m, 0.5 H), 2.60–2.50 (m, 0.5H), 2.08–1.98 (m, 1H), 1.75–1.66 (m, 0.5H), 1.65–1.57 (m, 0.5H), 1.55–1.36 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.18–1.02 (m, 1H), 0.94–0.80 (m, 6H); MS (ESI) *m/z* 514.7 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Methylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15c). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 12 mg (0.087 mmol) of 4-methylphenylboronic acid to give 20 mg (65%) of **15c** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.29–8.22 (m, 1H), 7.58–7.38 (m, 5H), 7.37–7.16 (m, 5H), 7.02–6.92 (m, 1H), 5.13–5.06 (m, 1H), 4.48–4.37 (m, 1H), 3.83–3.68 (m, 1H), 3.24–3.12 (m, 1H), 2.73–2.65 (m, 0.5 H), 2.60–2.50 (m, 0.5H), 2.39 (s, 3H), 2.08–1.96 (m, 1H), 1.76–1.55 (m, 1H), 1.54–1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.17–1.00 (m, 1H), 0.92–0.78 (m, 6H); MS (ESI) *m/z* 528.7 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Ethylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15d). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 13 mg (0.087 mmol) of 4-ethylphenylboronic acid to give 25 mg (80%) of **15d** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.28–8.23 (m, 1H), 7.58–7.38 (m, 5H), 7.37–7.15 (m, 5H), 7.04–6.95 (m, 1H), 5.15–5.05 (m, 1H), 4.50–4.37 (m, 1H), 3.85–3.68 (m, 1H), 3.25–3.14 (m, 1H), 2.76–2.66 (m, 2.5 H), 2.60–2.48 (m, 0.5H), 2.10–1.96 (m, 1H), 1.76–1.54 (m, 1H), 1.53–1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.28 (t, J = 7.5 Hz, 3H), 1.17–1.00 (m, 1H), 0.93–0.78 (m, 6H); MS (ESI) *m/z* 542.6 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Isobutylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15e). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 16 mg (0.087 mmol) of 4-isobutylphenylboronic acid to give 23 mg (77%) of **15e** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.28–8.23 (m, 1H), 7.60–7.38 (m, 5H), 7.34–7.15 (m, 5H), 7.04–6.95 (m, 1H), 5.14–5.05 (m, 1H), 4.50–4.36 (m, 1H), 3.86–3.68 (m, 1H), 3.24–3.14 (m, 1H), 2.74–2.65 (m, 0.5 H), 2.60–2.46 (m, 2.5H), 2.10–1.82 (m, 2H), 1.76–1.54 (m, 1H), 1.53–1.36 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.16–1.00 (m, 1H), 0.98–0.78 (m, 12H); MS (ESI) *m/z* 570.6 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Cyclohexylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15f). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 18 mg (0.087 mmol) of 4-cyclohexylphenylboronic acid to give 28 mg (81%) of **15f** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.28–8.21

(m, 1H), 7.58–7.40 (m, 5H), 7.32–7.12 (m, 5H), 7.02–6.92 (m, 1H), 5.15–5.05 (m, 1H), 4.50–4.36 (m, 1H), 3.88–3.68 (m, 1H), 3.26–3.13 (m, 1H), 2.75–2.64 (m, 0.5 H), 2.60–2.48 (m, 1.5H), 2.05–1.71 (m, 7H), 1.69–1.25 (m, 8H), 1.47 and 1.43 (2s, 9H), 1.17–1.00 (m, 1H), 0.96–0.80 (m, 6H); MS (ESI) *m/z* 596.9 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Trifluoromethylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15g). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 17 mg (0.087 mmol) of 4-trifluoromethylphenylboronic acid to give 25 mg (74%) of **15g** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.30–8.22 (m, 1H), 7.72–7.40 (m, 7H), 7.38–7.16 (m, 3H), 7.02–6.93 (m, 1H), 5.13–5.02 (m, 1H), 4.50–4.38 (m, 1H), 3.84–3.65 (m, 1H), 3.28–3.15 (m, 1H), 2.76–2.65 (m, 0.5 H), 2.61–2.48 (m, 0.5H), 2.08–1.96 (m, 1H), 1.76–1.55 (m, 1H), 1.54–1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.18–1.00 (m, 1H), 0.94–0.78 (m, 6H); MS (ESI) *m/z* 582.7 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Fluorobiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15h). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 12 mg (0.087 mmol) of 4-fluorophenylboronic acid to give 20 mg (74%) of **15h** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.30–8.22 (m, 1H), 7.56–7.48 (m, 4H), 7.30–7.18 (m, 6H), 7.02–7.92 (m, 1H), 5.12–5.05 (m, 1H), 4.52–4.38 (m, 1H), 3.82–3.65 (m, 1H), 3.25–3.12 (m, 1H), 2.76–2.65 (m, 0.5 H), 2.61–2.48 (m, 0.5H), 2.08–1.95 (m, 1H), 1.78–1.55 (m, 1H), 1.54–1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.18–1.00 (m, 1H), 0.95–0.80 (m, 6H); MS (ESI) *m/z* 532.5 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Chlorobiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15i). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 14 mg (0.087 mmol) of 4-chlorophenylboronic acid to give 22 mg (74%) of **15i** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.30–8.22 (m, 1H), 7.55–7.36 (m, 6H), 7.30–7.15 (m, 4H), 7.02–7.95 (m, 1H), 5.10–5.00 (m, 1H), 4.50–4.35 (m, 1H), 3.80–3.62 (m, 1H), 3.26–3.15 (m, 1H), 2.76–2.65 (m, 0.5 H), 2.61–2.48 (m, 0.5H), 2.08–1.95 (m, 1H), 1.75–1.55 (m, 1H), 1.54–1.37 (m, 3H), 1.47 and 1.42 (2s, 9H), 1.16–1.00 (m, 1H), 0.95–0.80 (m, 6H); MS (ESI) *m/z* 548.5 [M + H]⁺.

tert-Butyl [(2S,3S)-1-((4'-Acetylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-methylpentan-2-yl]carbamate (15j). The procedure for **15a** was followed using 30 mg (0.058 mmol) of **14** and 14 mg (0.087 mmol) of 4-acetylphenylboronic acid to give 25 mg (76%) of **15j** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.30–8.21 (m, 1H), 8.06–7.98 (m, 2H), 7.68–7.48 (m, 5H), 7.38–7.15 (m, 3H), 7.02–7.93 (m, 1H), 5.10–5.00 (m, 1H), 4.50–4.36 (m, 1H), 3.80–3.62 (m, 1H), 3.28–3.15 (m, 1H), 2.75–2.65 (m, 0.5 H), 2.64 (s, 3H), 2.61–2.48 (m, 0.5H), 2.08–1.95 (m, 1H), 1.76–1.55 (m, 1H), 1.54–1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.16–0.98 (m, 1H), 0.92–0.78 (m, 6H); MS (ESI) *m/z* 557.2 [M + H]⁺.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-Amino-3-methylpentyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (1). A solution of **15a** (150 mg, 0.27 mmol) and 4 M HCl in dioxane (2 mL) in CH₂Cl₂ (5 mL) was stirred at room temperature for 6 h. The solvent was removed under reduced pressure. The resulting residue was triturated with Et₂O to give **1** (135 mg, 95%, 1:1 diastereomeric mixture) as a white solid: ¹H NMR (300 MHz; CD₃OD) δ 8.66–8.54 (m, 1H), 8.37–8.23 (m, 1H), 7.82–7.44 (m, 8H), 7.32–7.22 (m, 2H), 4.43 (dd, J = 15.0, 9.0 Hz, 0.5H), 4.28 (dd, J = 15.0, 9.0 Hz, 0.5H), 3.82 (d, J = 15.0 Hz, 0.5H), 3.68 (d, J = 15.0 Hz, 0.5H), 3.46–3.35 (m, 1H), 3.11–3.02 (m, 0.5H), 3.00–2.90 (m, 0.5H), 2.62 (t, J = 7.5 Hz, 2H), 2.22–2.08 (m, 1H), 2.02–1.88 (m, 1H), 1.87–1.62 (m, 4H), 1.50–1.12 (m, 2H), 1.02–0.78 (m, 9H); HRMS (ESI) calcd. for C₃₀H₃₇N₃O [M + H]⁺: 456.3009. Found: 456.3020.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-Amino-3-methylpentyl-(biphenyl-4-yl)amide Dihydrochloride (4a). The procedure for **1** was followed using 20 mg (0.039 mmol) of **15b** and 1 mL of 4 M HCl in dioxane to give 17 mg (90%) of **4a** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CD₃OD) δ 8.28–8.21

(m, 1H), 7.72–7.52 (m, 5H), 7.48–7.32 (m, 5H), 7.30–7.23 (m, 1H), 7.19–7.10 (m, 1H), 4.40–4.22 (m, 1H), 3.80–3.66 (m, 1H), 3.40–3.22 (m, 1H), 2.70–2.53 (m, 1H), 2.05–1.90 (m, 1H), 1.84–1.62 (m, 2H), 1.50–1.15 (m, 3H), 0.99 and 0.97 (2d, $J = 6.0$ Hz, 3H), 0.90–0.80 (m, 3H); HRMS (ESI) calcd. for $C_{27}H_{31}N_3O$ $[M + H]^+$: 414.2541. Found: 414.2540.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-methylbiphenyl-4-yl)amide Dihydrochloride (**4b**). The procedure for **1** was followed using 20 mg (0.038 mmol) of **15c** and 1 mL of 4 M HCl in dioxane to give 18 mg (95%) of **4b** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.68–8.55 (m, 1H), 8.42–8.30 (m, 1H), 7.88–7.40 (m, 8H), 7.30–7.20 (m, 2H), 4.50–4.40 (m, 0.5H), 4.40–4.28 (m, 0.5H), 3.88–3.56 (m, 1H), 3.48–3.38 (m, 1H), 3.12–3.05 (m, 0.5H), 3.05–2.96 (m, 0.5H), 2.37 (s, 3H), 2.22–2.10 (m, 1H), 2.10–1.88 (m, 1H), 1.87–1.60 (m, 2H), 1.48–1.15 (m, 2H), 1.06–0.80 (m, 6H); HRMS (ESI) calcd. for $C_{28}H_{33}N_3O$ $[M + H]^+$: 428.2696. Found: 428.2701.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-ethylbiphenyl-4-yl)amide Dihydrochloride (**4c**). The procedure for **1** was followed using 20 mg (0.037 mmol) of **15d** and 1 mL of 4 M HCl in dioxane to give 18 mg (95%) of **4c** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.70–8.58 (m, 1H), 8.45–8.30 (m, 1H), 7.88–7.45 (m, 8H), 7.32–7.20 (m, 2H), 4.52–4.40 (m, 0.5H), 4.38–4.28 (m, 0.5H), 3.88–3.56 (m, 1H), 3.48–3.35 (m, 1H), 3.15–3.05 (m, 0.5H), 3.05–2.95 (m, 0.5H), 2.80–2.60 (m, 2H), 2.25–2.10 (m, 1H), 2.10–1.90 (m, 1H), 1.87–1.60 (m, 2H), 1.50–1.10 (m, 5H), 1.08–0.80 (m, 6H); HRMS (ESI) calcd. for $C_{29}H_{35}N_3O$ $[M + H]^+$: 442.2853. Found: 442.2867.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-isobutylbiphenyl-4-yl)amide Dihydrochloride (**4d**). The procedure for **1** was followed using 20 mg (0.035 mmol) of **15e** and 1 mL of 4 M HCl in dioxane to give 17 mg (90%) of **4d** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.68–8.58 (m, 1H), 8.40–8.28 (m, 1H), 7.92–7.43 (m, 8H), 7.30–7.20 (m, 2H), 4.50–4.40 (m, 0.5H), 4.38–4.25 (m, 0.5H), 3.88–3.60 (m, 1H), 3.50–3.38 (m, 1H), 3.13–3.05 (m, 0.5H), 3.05–2.90 (m, 0.5H), 2.51 (d, $J = 6.0$ Hz, 2H), 2.25–2.10 (m, 1H), 2.05–1.60 (m, 4H), 1.50–1.20 (m, 2H), 1.10–0.76 (m, 12H); HRMS (ESI) calcd. for $C_{31}H_{39}N_3O$ $[M + H]^+$: 470.3166. Found: 470.3178.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-cyclohexylbiphenyl-4-yl)amide Dihydrochloride (**4e**). The procedure for **1** was followed using 20 mg (0.034 mmol) of **15f** and 1 mL of 4 M HCl in dioxane to give 19 mg (98%) of **4e** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.55–8.40 (m, 1H), 8.15–8.00 (m, 1H), 7.75–7.40 (m, 8H), 7.35–7.20 (m, 2H), 4.48–4.20 (m, 1H), 3.88–3.68 (m, 1H), 3.42–3.35 (m, 1H), 2.98–2.88 (m, 1H), 2.68–2.48 (m, 1H), 2.20–2.00 (m, 1H), 1.98–1.70 (m, 7H), 1.66–1.10 (m, 8H), 1.05–0.78 (m, 6H); HRMS (ESI) calcd. for $C_{33}H_{41}N_3O$ $[M + H]^+$: 496.3322. Found: 496.3323.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-trifluoromethylbiphenyl-4-yl)amide Dihydrochloride (**4f**). The procedure for **1** was followed using 20 mg (0.034 mmol) of **15g** and 1 mL of 4 N HCl in dioxane to give 18 mg (95%) of **4f** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.70–8.58 (m, 1H), 8.42–8.30 (m, 1H), 7.90–7.50 (m, 10H), 4.55–4.40 (m, 0.5H), 4.40–4.26 (m, 0.5H), 3.90–3.60 (m, 1H), 3.50–3.38 (m, 1H), 3.15–3.05 (m, 0.5H), 3.05–2.92 (m, 0.5H), 2.25–2.10 (m, 1H), 2.10–1.92 (m, 1H), 1.92–1.62 (m, 2H), 1.50–1.15 (m, 2H), 1.08–0.80 (m, 6H); HRMS (ESI) calcd. for $C_{28}H_{30}F_3N_3O$ $[M + H]^+$: 482.2414. Found: 482.2416.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-fluorobiphenyl-4-yl)amide Dihydrochloride (**4g**). The procedure for **1** was followed using 20 mg (0.038 mmol) of **15h** and 1 mL of 4 M HCl in dioxane to give 18 mg (94%) of **4g** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.70–8.58 (m, 1H), 8.45–8.35 (m, 1H), 7.90–7.50 (m, 8H), 7.25–7.10 (m, 2H), 4.52–4.40 (m, 0.5H), 4.40–4.25 (m, 0.5H), 3.90–3.60 (m, 1H), 3.52–3.40 (m, 1H), 3.16–3.06 (m, 0.5H), 3.05–2.92 (m, 0.5H), 2.25–2.10 (m, 1H), 2.10–1.92 (m, 1H), 1.92–1.60 (m, 2H), 1.50–1.18 (m, 2H), 1.10–0.80 (m, 6H); HRMS (ESI) calcd. for $C_{27}H_{30}FN_3O$ $[M + H]^+$: 432.2446. Found: 432.2453.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-chlorobiphenyl-4-yl)amide Dihydrochloride (**4h**). The procedure for **1** was followed using 20 mg (0.036 mmol) of **15i** and 1 mL of 4 M HCl in dioxane to give 18 mg (96%) of **4h** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.72–8.58 (m, 1H), 8.45–8.35 (m, 1H), 7.90–7.55 (m, 8H), 7.55–7.40 (m, 2H), 4.55–4.42 (m, 0.5H), 4.40–4.25 (m, 0.5H), 3.90–3.60 (m, 1H), 3.50–3.40 (m, 1H), 3.18–3.07 (m, 0.5H), 3.06–2.96 (m, 0.5H), 2.25–2.10 (m, 1H), 2.08–1.90 (m, 1H), 1.90–1.68 (m, 2H), 1.58–1.12 (m, 2H), 1.10–0.80 (m, 6H); HRMS (ESI) calcd. for $C_{27}H_{30}ClN_3O$ $[M + H]^+$: 448.2150. Found: 448.2162.

(1*R**,2*R**)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-acetylphenyl-4-yl)amide Dihydrochloride (**4i**). The procedure for **1** was followed using 20 mg (0.036 mmol) of **15j** and 1 mL of 4 M HCl in dioxane to give 17 mg (90%) of **4i** as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD_3OD) δ 8.35–8.22 (m, 1H), 8.05–7.92 (m, 2H), 7.90–7.75 (m, 1H), 7.72–7.60 (m, 4H), 7.52–7.40 (m, 2H), 7.35–7.22 (m, 2H), 4.38–4.16 (m, 1H), 3.80–3.55 (m, 1H), 3.38–3.20 (m, 1H), 2.80–2.60 (m, 1H), 2.54 (s, 3H), 2.00–1.88 (m, 1H), 1.78–1.60 (m, 2H), 1.50–1.10 (m, 3H), 0.95–0.70 (m, 6H); HRMS (ESI) calcd. for $C_{29}H_{33}N_3O_2$ $[M + H]^+$: 456.2646. Found: 456.2658.

tert-Butyl (1*R*,2*R*)-2-(Pyridin-2-yl)cyclopropanecarboxylate ((1*R*,2*R*)-**9**). An oven-dried Schlenk tube, that was previously charged with chiral porphyrin catalyst [Co(3,5-Di*t*Bu-ChenPhyrin)]¹¹ (3.4 mg, 0.0025 mmol) and DMAP (15 mg, 0.13 mmol), was evacuated and backfilled with nitrogen gas. Toluene (0.5 mL) and 2-vinylpyridine (**8**) (26 mg, 0.25 mmol) were added, followed by the remaining solvent (total 1.0 mL). The Schlenk tube was then placed in a -20 °C cooling bath, and *tert*-butyl diazoacetate (41 μ L, 0.3 mmol) was added dropwise. After addition, the tube was purged with nitrogen for 2 min and the mixture was stirred at -20 °C for 12 h, then at 0 °C for 12 h. After warming to room temperature, the reaction was continued for another 24 h. Flash column chromatography of the crude mixture on silica gel using 10% EtOAc in hexanes afforded (1*R*,2*R*)-**9** (35 mg, 64%) as a colorless oil. Assignment of the absolute configuration was made based on the analogy to similar compounds with known absolute configurations synthesized using the same chiral catalyst.¹¹ The enantiomeric excess (97% ee) was determined by HPLC (ChiralPak AD-H column; 0.5% isopropanol/hexanes; flow rate 0.8 mL/min; detection 254 nm; retention time 10.6 min).

(1*R*,2*R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid Hydrochloride ((1*R*,2*R*)-**10**). To a solution of (1*R*,2*R*)-**9** (110 mg, 0.50 mmol) in CH_2Cl_2 (5 mL) was added 4 M HCl in dioxane (2 mL), and the reaction was stirred at room temperature for 5 h. The solvent was removed under reduced pressure. The residue was triturated with CH_2Cl_2 /Et₂O to afford (1*R*,2*R*)-**10** (95 mg, 95%) as a white solid: mp 155–157 °C; $[\alpha]_D^{23}$ -206.8° (c 0.5, CH_3OH).

tert-Butyl [(2*S*,3*S*)-1-{4-Bromophenyl}-(1*R*,2*R*)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino-3-methylpentan-2-yl]carbamate ((1*R*,2*R*)-**14**). The procedure for **14** was followed using 108 mg (0.29 mmol) of **13** and 70 mg (0.35 mmol) of (1*R*,2*R*)-**10** to give 97 mg (65%) of (1*R*,2*R*)-**14** as a white foam: $[\alpha]_D^{23}$ -21.0° (c 0.58, CH_3OH); 1H NMR (300 MHz; $CDCl_3$) δ 8.30 (d, $J = 6.0$ Hz, 1H), 7.56–7.40 (m, 3H), 7.22–7.06 (m, 3H), 7.06–6.98 (m, 1H), 4.96 (d, $J = 9.0$ Hz, 1H), 4.36 (t, $J = 12.0$ Hz, 1H), 3.78–3.65 (m, 1H), 3.12 (dd, $J = 12.0, 3.0$ Hz, 1H), 2.67 (ddd, $J = 9.0, 6.0, 3.0$ Hz, 1H), 1.93–1.86 (m, 1H), 1.61–1.53 (m, 1H), 1.52–1.41 (m, 3H), 1.45 (s, 9H), 1.15–1.02 (m, 1H), 0.87 (d, $J = 6.0$ Hz, 3H), 0.85 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (75 MHz; $CDCl_3$) δ 173.2, 159.3, 156.4, 149.4, 141.3, 136.0, 133.1, 130.1, 122.7, 121.9, 121.2, 79.0, 54.0, 50.3, 38.3, 28.6, 27.5, 25.3, 24.7, 18.3, 15.2, 11.9; MS (ESI) m/z 516.5 $[M + H]^+$ (^{79}Br), 518.4 $[M + H]^+$ (^{81}Br). The diastereomeric excess (>97% de) was determined by HPLC (ChiralPak IA column; 5% EtOH/hexanes; flow rate 1 mL/min; detection 220 nm; retention time 9.1 min).

tert-Butyl [(2*S*,3*S*)-1-{4-Bromophenyl}-(1*S*,2*S*)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino-3-methylpentan-2-yl]carbamate ((1*S*,2*S*)-**14**). The diastereomeric mixture **14** (350 mg) was separated to (1*R*,2*R*)-**14** (140 mg) and (1*S*,2*S*)-**14** (137 mg) by preparative HPLC using ChiralPak IA column: mobile phase, 5% EtOH/hexanes; flow rate, 5 mL/min; detection 220 nm. The diastereomeric excess

(de) of both of separated compounds was determined to be >99% by HPLC (ChiralPak IA column; 5% EtOH/hexanes; flow rate 1 mL/min; detection 220 nm; retention time, (1*R*,2*R*)-**14**: 9.1 min, (1*S*,2*S*)-**14**: 11.5 min). (1*S*,2*S*)-**14**: White foam; $[\alpha]_D^{25} +52.7^\circ$ (c 0.55, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 8.30 (d, *J* = 6.0 Hz, 1H), 7.52 (td, *J* = 9.0, 3.0 Hz, 1H), 7.40 (d, *J* = 6.0 Hz, 2H), 7.16 (d, *J* = 9.0 Hz, 1H), 7.12–6.99 (m, 3H), 4.96 (d, *J* = 9.0 Hz, 1H), 4.38 (dd, *J* = 15.0, 12.0 Hz, 1H), 3.72–3.58 (m, 1H), 3.15 (dd, *J* = 15.0, 3.0 Hz, 1H), 2.52 (ddd, *J* = 9.0, 6.0, 3.0 Hz, 1H), 1.97–1.90 (m, 1H), 1.70–1.63 (m, 1H), 1.54–1.38 (m, 3H), 1.40 (s, 9H), 1.14–1.02 (m, 1H), 0.87 (d, *J* = 6.0 Hz, 3H), 0.84 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 173.1, 159.2, 156.2, 149.5, 141.1, 135.9, 132.9, 130.1, 122.5, 121.8, 121.2, 78.9, 53.8, 50.0, 38.2, 28.6, 28.1, 25.3, 24.7, 17.7, 15.2, 11.9; MS (ESI) *m/z* 516.5 [M + H]⁺ (⁷⁹Br), 518.4 [M + H]⁺ (⁸¹Br).

(1*R*,2*R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (**2**). The procedure for **15a** was followed using 120 mg (0.23 mmol) of (1*R*,2*R*)-**14**, followed by deprotection of the Boc protecting group with 4 M HCl in dioxane, to give 97 mg (80% over two steps) of **2** as a white solid: mp 125 °C (fusion); $[\alpha]_D^{25} +6.3^\circ$ (c 1, CH₃OH); ¹H NMR (300 MHz; CD₃OD) δ 8.58 (d, *J* = 6.0 Hz, 1H), 8.28 (t, *J* = 9.0 Hz, 1H), 7.78–7.52 (m, 6H), 7.51 (d, *J* = 9.0 Hz, 2H), 7.27 (d, *J* = 9.0 Hz, 2H), 4.29 (dd, *J* = 15.0, 9.0 Hz, 1H), 3.83 (d, *J* = 12.0 Hz, 1H), 3.48–3.38 (m, 1H), 3.01–2.90 (m, 1H), 2.62 (t, *J* = 7.5 Hz, 2H), 2.22–2.12 (m, 1H), 2.02–1.92 (m, 1H), 1.90–1.75 (m, 1H), 1.75–1.60 (m, 3H), 1.50–1.35 (m, 1H), 1.35–1.15 (m, 1H), 1.05–0.90 (m, 6H), 0.86 (t, *J* = 6.0 Hz, 3H); ¹³C NMR (75 MHz; CD₃OD) δ 173.4, 157.6, 146.6, 143.9, 143.3, 142.9, 141.6, 138.2, 130.2, 129.8, 129.5, 127.9, 125.5, 125.1, 56.6, 50.9, 38.7, 37.2, 27.4, 26.5, 25.7, 25.2, 18.1, 14.2, 14.2, 11.7; HRMS (ESI) calcd. for C₃₀H₃₇N₃O [M + H]⁺: 456.3009. Found: 456.3023. The diastereomeric excess (>99% de) was determined by HPLC (XTerra MS C-18 column; gradient 40–60% of (0.1%TFA/MeCN)/(0.1%TFA/water); flow rate 1 mL/min; detection 254 nm; retention time 5.66 min).

(1*S*,2*S*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2*S*,3*S*)-2-Amino-3-methylpentyl]-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (**3**). The procedure for **15a** was followed using 120 mg (0.23 mmol) of (1*S*,2*S*)-**14**, followed by deprotection of the Boc protecting group with 4 M HCl in dioxane, to give 98 mg (81% over two steps) of **3** as a white solid: mp 122 °C (fusion); $[\alpha]_D^{25} -91.3^\circ$ (c 1, CH₃OH); ¹H NMR (300 MHz; CD₃OD) δ 8.62 (br d, *J* = 3.0 Hz, 1H), 8.31 (br t, *J* = 7.5 Hz, 1H), 7.80–7.58 (m, 6H), 7.49 (d, *J* = 9.0 Hz, 2H), 7.26 (d, *J* = 9.0 Hz, 2H), 4.46 (dd, *J* = 15.0, 9.0 Hz, 1H), 3.68 (d, *J* = 15.0 Hz, 1H), 3.46–3.38 (m, 1H), 3.12–3.02 (m, 1H), 2.61 (t, *J* = 7.5 Hz, 2H), 2.25–2.05 (m, 1H), 1.98–1.86 (m, 1H), 1.86–1.60 (m, 4H), 1.45–1.15 (m, 2H), 1.10–0.90 (m, 6H), 0.82 (t, *J* = 6.0 Hz, 3H); ¹³C NMR (75 MHz; CD₃OD) δ 173.3, 157.5, 146.7, 143.9, 143.3, 142.9, 141.4, 138.2, 130.2, 130.0, 129.4, 127.9, 125.6, 125.3, 56.5, 50.6, 38.7, 37.4, 27.0, 26.7, 25.7, 25.6, 17.2, 14.1, 11.8; HRMS (ESI) calcd. for C₃₀H₃₇N₃O [M + H]⁺: 456.3009. Found: 456.3018. The diastereomeric excess (>99% de) was determined by HPLC (XTerra MS C-18 column; gradient 40–60% of (0.1%TFA/MeCN)/(0.1%TFA/water); flow rate 1 mL/min; detection 254 nm; retention time 6.35 min).

tert-Butyl 2-[(4-Bromophenyl)amino]ethylcarbamate (**18a**). The procedure for **13** was followed using 1.03 g (5.96 mmol) of **11** and 0.95 g (5.96 mmol) of *N*-Boc-2-aminoacetaldehyde (**17a**) to give 1.38 g (50%) of **18a** as a yellow oily residue: ¹H NMR (300 MHz; CDCl₃) δ 7.23 (d, *J* = 9.0 Hz, 2H), 6.48 (d, *J* = 9.0 Hz, 2H), 4.80 (br s, 1H), 4.10 (br s, 1H), 3.41–3.30 (m, 2H), 3.30–3.26 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz; CDCl₃) δ 156.5, 147.1, 131.9, 114.2, 108.8, 79.6, 44.4, 40.0, 28.4; MS (ESI) *m/z* 315.1 [M + H]⁺ (⁷⁹Br), 317.2 [M + H]⁺ (⁸¹Br).

tert-Butyl [(2*S*)-1-[(4-Bromophenyl)amino]propan-2-yl]carbamate (**18b**). The procedure for **13** was followed using 247 mg (1.44 mmol) of **11** and 250 mg (1.44 mmol) of *N*-Boc-L-alaninal (**17b**) to give 410 mg (86%) of **18b** as a white solid: mp 115–117 °C; $[\alpha]_D^{25} +3.1^\circ$ (c 0.52, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 7.23 (d, *J* = 9.0 Hz, 2H), 6.48 (d, *J* = 9.0 Hz, 2H), 4.48 (br s, 1H), 4.12 (br s, 1H), 4.00–3.86 (m, 1H), 3.18–2.98 (m, 2H), 1.45 (s, 9H), 1.21 (d,

J = 6.0 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 156.0, 147.3, 131.9, 114.1, 108.7, 79.7, 50.6, 46.3, 28.4, 19.0; MS (ESI) *m/z* 329.3 [M + H]⁺ (⁷⁹Br), 331.2 [M + H]⁺ (⁸¹Br).

tert-Butyl [(2*S*)-1-[(4'-Propylbiphenyl-4-yl)amino]-3-methylbutan-2-yl]carbamate (**18c**). The procedure for **13** was followed using 150 mg (0.71 mmol) of 4-(4'-propylphenyl)aniline (**16**) and 143 mg (0.71 mmol) of aldehyde **17c**, prepared by oxidation of *N*-Boc-L-valinol, to give 185 mg (66%) of **18c** as a white solid: mp 83–85 °C; $[\alpha]_D^{25} +22.2^\circ$ (c 0.54, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 7.45 (d, *J* = 9.0 Hz, 2H), 7.42 (d, *J* = 9.0 Hz, 2H), 7.20 (d, *J* = 9.0 Hz, 2H), 6.65 (d, *J* = 9.0 Hz, 2H), 4.51 (d, *J* = 6.0 Hz, 1H), 4.12 (br s, 1H), 3.80–3.65 (m, 1H), 3.35–3.20 (m, 1H), 3.12–3.00 (m, 1H), 2.60 (t, *J* = 7.5 Hz, 2H), 1.95–1.80 (m, 1H), 1.75–1.58 (m, 2H), 1.45 (s, 9H), 1.05–0.90 (m, 9H); ¹³C NMR (75 MHz; CDCl₃) δ 156.8, 147.8, 140.5, 138.8, 130.3, 128.9, 127.8, 126.2, 113.0, 79.5, 55.7, 47.1, 37.8, 30.6, 28.5, 24.7, 19.6, 18.2, 14.0; MS (ESI) *m/z* 397.5 [M + H]⁺.

tert-Butyl [(2*S*)-1-[(4'-Propylbiphenyl-4-yl)amino]-4-methylpentan-2-yl]carbamate (**18d**). The procedure for **13** was followed using 90 mg (0.43 mmol) of **16** and 93 mg (0.43 mmol) of aldehyde **17d**, prepared by oxidation of *N*-Boc-L-leucinol, to give 120 mg (68%) of **18d** as a white solid: mp 98–100 °C; $[\alpha]_D^{25} +2.4^\circ$ (c 0.54, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 7.45 (d, *J* = 9.0 Hz, 2H), 7.42 (d, *J* = 9.0 Hz, 2H), 7.22 (d, *J* = 9.0 Hz, 2H), 6.66 (d, *J* = 9.0 Hz, 2H), 4.41 (br s, 1H), 4.21 (br s, 1H), 4.00–3.82 (m, 1H), 3.32–3.20 (m, 1H), 3.12–3.00 (m, 1H), 2.62 (t, *J* = 7.5 Hz, 2H), 1.80–1.60 (m, 3H), 1.45 (s, 9H), 1.43–1.35 (m, 2H), 1.05–0.90 (m, 9H); ¹³C NMR (75 MHz; CDCl₃) δ 156.3, 147.7, 140.5, 138.7, 130.2, 128.7, 127.8, 126.1, 112.9, 79.5, 49.9, 49.0, 42.5, 37.7, 28.4, 25.0, 24.6, 23.1, 22.1, 13.9; MS (ESI) *m/z* 411.5 [M + H]⁺.

tert-Butyl [(2*S*)-1-[(4-Bromophenyl)amino]-3-phenylpropan-2-yl]carbamate (**18e**). The procedure for **13** was followed using 172 mg (1.00 mmol) of **11** and 250 mg (1.00 mmol) of *N*-Boc-L-phenylalaninal (**17e**) to give 350 mg (86%) of **18e** as a white solid: mp 124–126 °C; $[\alpha]_D^{25} +12.2^\circ$ (c 0.53, CH₃OH); ¹H NMR (300 MHz; CDCl₃) δ 7.36–7.15 (m, 7H), 6.43 (d, *J* = 9.0 Hz, 2H), 4.51 (br s, 1H), 4.15–3.98 (m, 2H), 3.26–3.15 (m, 1H), 3.10–2.92 (m, 1H), 2.96–1.80 (m, 2H), 1.41 (s, 9H); ¹³C NMR (75 MHz; CDCl₃) δ 156.0, 147.1, 137.3, 131.9, 129.2, 128.7, 126.8, 114.3, 109.0, 79.8, 51.4, 47.9, 39.2, 28.3; MS (ESI) *m/z* 405.3 [M + H]⁺ (⁷⁹Br), 407.3 [M + H]⁺ (⁸¹Br).

tert-Butyl (2-[(4-Bromophenyl)-[(1*R**,2*R**)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino]ethyl)carbamate (**19a**). The procedure for **14** was followed using 180 mg (0.57 mmol) of **18a** and 136 mg (0.68 mmol) of racemic **10** to give 140 mg (53%) of **19a** as a yellow oil: ¹H NMR (300 MHz; CDCl₃) δ 8.31 (d, *J* = 6.0 Hz, 1H), 7.60–7.50 (m, 1H), 7.43 (d, *J* = 9.0 Hz, 2H), 7.21–7.00 (m, 4H), 5.05 (br s, 1H), 3.92–3.80 (m, 2H), 3.40–3.25 (m, 2H), 2.68–2.58 (m, 1H), 2.00–1.90 (m, 1H), 1.70–1.58 (m, 1H), 1.41 (s, 9H), 1.20–1.05 (m, 1H); MS (ESI) *m/z* 460.3 [M + H]⁺ (⁷⁹Br), 462.1 [M + H]⁺ (⁸¹Br). This product contained impurity as judged by ¹H NMR analysis, which was used in the next step without further purification.

tert-Butyl [(2*S*)-1-[(4-Bromophenyl)-[(1*R**,2*R**)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino]propan-2-yl]carbamate (**19b**). The procedure for **14** was followed using 99 mg (0.30 mmol) of **18b** and 72 mg (0.36 mmol) of racemic **10** to give 85 mg (60%) of **19b** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.30 (d, *J* = 6.0 Hz, 1H), 7.58–7.36 (m, 3H), 7.20–6.95 (m, 4H), 4.98 (d, *J* = 6.0 Hz, 1H), 4.22–4.05 (m, 1H), 3.92–3.70 (m, 1H), 3.32–3.18 (m, 2H), 2.68–2.60 (m, 0.5H), 2.60–2.46 (m, 0.5H), 1.95–1.80 (m, 1H), 1.68–1.52 (m, 1H), 1.43 and 1.41 (2s, 9H), 1.10 (d, *J* = 6.0 Hz, 3H); MS (ESI) *m/z* 474.4 [M + H]⁺ (⁷⁹Br), 476.5 [M + H]⁺ (⁸¹Br).

tert-Butyl (2*S*)-1-[(4'-Propylbiphenyl-4-yl)-[(1*R**,2*R**)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino]-3-methylbutan-2-yl]carbamate (**19c**). The procedure for **14** was followed using 120 mg (0.34 mmol) of **18c** and 81 mg (0.40 mmol) of racemic **10** to give 110 mg (60%) of **19c** as a 1:1 diastereomeric mixture: ¹H NMR (300 MHz; CDCl₃) δ 8.26–8.18 (m, 1H), 7.55–7.34 (m, 5H), 7.30–7.21 (m, 5H), 6.98–6.90 (m, 1H), 5.08–4.92 (m, 1H), 4.45–4.32 (m, 1H), 3.80–3.60 (m, 1H), 3.25–3.12 (m, 1H), 2.74–2.48 (m, 3H), 2.08–1.92 (m, 1H),

1.78–1.52 (m, 5H), 1.47 and 1.43 (2s, 9H), 1.00–0.80 (m, 9H); MS (ESI) m/z 542.6 $[M + H]^+$.

tert-Butyl (2S)-1-((4'-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-4-methylpentan-2-yl]-carbamate (19d). The procedure for **14** was followed using 90 mg (0.22 mmol) of **18d** and 53 mg (0.26 mmol) of racemic **10** to give 65 mg (53%) of **19d** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CDCl_3) δ 8.28–8.20 (m, 1H), 7.55–7.35 (m, 5H), 7.32–7.12 (m, 5H), 7.00–6.90 (m, 1H), 4.90–4.80 (m, 1H), 4.28–4.12 (m, 1H), 4.00–3.80 (m, 1H), 3.38–3.20 (m, 1H), 2.75–2.50 (m, 3H), 2.10–1.90 (m, 1H), 1.76–1.52 (m, 5H), 1.45 and 1.41 (2s, 9H), 1.40–1.12 (m, 2H), 1.02–0.80 (m, 9H); MS (ESI) m/z 556.8 $[M + H]^+$.

tert-Butyl [(2S)-1-(4-Bromophenyl)-[(1R*,2R*)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino]-3-phenylpropan-2-yl]carbamate (19e). The procedure for **14** was followed using 99 mg (0.30 mmol) of **18e** and 72 mg (0.36 mmol) of racemic **10** to give 85 mg (60%) of **19e** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CDCl_3) δ 8.29 (d, J = 6.0 Hz, 1H), 7.55–7.30 (m, 3H), 7.30–6.90 (m, 9H), 5.05–4.92 (m, 1H), 4.28–3.90 (m, 2H), 3.30–3.20 (m, 1H), 2.88–2.48 (m, 3H), 1.95–1.82 (m, 1H), 1.70–1.50 (m, 1H), 1.39 and 1.37 (2s, 9H), 1.32–1.20 (m, 1H); MS (ESI) m/z 550.4 $[M + H]^+$ (^{79}Br), 552.5 $[M + H]^+$ (^{81}Br).

tert-Butyl (2-((4'-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)-cyclopropanecarbonyl]amino)ethyl)carbamate (20a). The procedure for **15a** was followed using 140 mg (0.30 mmol) of **19a** and 83 mg (0.47 mmol) of 4-propylphenylboronic acid to give 80 mg (53%) of **20a**: ^1H NMR (300 MHz; CDCl_3) δ 8.22 (d, J = 6.0 Hz, 1H), 7.55–7.40 (m, 5H), 7.25–7.12 (m, 5H), 7.00–6.90 (m, 1H), 5.17 (br s, 1H), 3.90 (t, J = 6.0 Hz, 2H), 3.42–3.25 (m, 3H), 2.62 (t, J = 7.5 Hz, 2H), 2.10–1.98 (m, 1H), 1.75–1.60 (m, 2H), 1.55–1.35 (m, 2H), 1.42 (s, 9H), 0.97 (t, J = 6.0 Hz, 3H); ^{13}C NMR (75 MHz; CDCl_3) δ 172.9, 159.4, 156.1, 149.3, 142.3, 141.0, 137.4, 135.8, 129.7, 129.0, 128.2, 128.1, 126.9, 122.4, 121.0, 79.1, 49.2, 39.7, 37.7, 28.4, 27.7, 24.9, 24.5, 17.7, 13.9; MS (ESI) m/z 500.8 $[M + H]^+$.

tert-Butyl [(2S)-1-((4'-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)propan-2-yl]carbamate (20b). The procedure for **15a** was followed using 50 mg (0.11 mmol) of **19b** and 29 mg (0.16 mmol) of 4-propylphenylboronic acid to give 45 mg (80%) of **20b** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CDCl_3) δ 8.28–8.18 (m, 1H), 7.56–7.38 (m, 5H), 7.28–7.10 (m, 5H), 7.00–6.90 (m, 1H), 5.20–5.06 (m, 1H), 4.32–4.15 (m, 1H), 3.96–3.78 (m, 1H), 3.38–3.22 (m, 1H), 2.70–2.48 (m, 3H), 2.06–1.90 (m, 2H), 1.78–1.58 (m, 3H), 1.45 and 1.43 (2s, 9H), 1.12 (d, J = 6.0 Hz, 3H), 0.97 (t, J = 7.5 Hz, 3H); MS (ESI) m/z 514.6 $[M + H]^+$.

tert-Butyl [(2S)-1-((4'-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino)-3-phenylpropan-2-yl]carbamate (20e). The procedure for **15a** was followed using 90 mg (0.16 mmol) of **19e** and 44 mg (0.24 mmol) of 4-propylphenylboronic acid to give 75 mg (80%) of **20e** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CDCl_3) δ 8.26–8.15 (m, 1H), 7.55–7.38 (m, 6H), 7.28–7.05 (m, 9H), 7.00–6.90 (m, 1H), 5.16–5.05 (m, 1H), 4.35–4.18 (m, 1H), 4.15–3.95 (m, 1H), 3.34–3.22 (m, 1H), 2.88–2.45 (m, 5H), 2.05–1.90 (m, 1H), 1.75–1.50 (m, 3H), 1.41 and 1.40 (2s, 9H), 1.30–1.20 (m, 1H), 0.97 (t, J = 7.5 Hz, 3H); MS (ESI) m/z 590.8 $[M + H]^+$.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [2-Aminoethyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (5a). The procedure for **1** was followed using 60 mg (0.12 mmol) of **20a** and 1 mL of 4 M HCl in dioxane to give 52 mg (92%) of **5a** as a light yellow foam: ^1H NMR (300 MHz; CD_3OD) δ 8.56 (br s, 1H), 8.23 (br t, 1H), 7.50–7.63 (m, 3H), 7.62–7.43 (m, 5H), 7.27 (d, J = 9.0 Hz, 2H), 4.25–3.98 (m, 2H), 3.22–3.10 (m, 2H), 3.00–2.78 (m, 1H), 2.63 (t, J = 7.5 Hz, 2H), 2.18–2.08 (m, 1H), 1.94–1.82 (m, 1H), 1.72–1.60 (m, 3H), 0.96 (t, J = 7.5 Hz, 3H); ^{13}C NMR (75 MHz; CD_3OD) δ 173.1, 157.9, 146.2, 144.1, 143.9, 143.0, 141.4, 138.2, 130.2, 130.0, 129.6, 128.0, 125.5, 125.3, 39.9, 38.7, 27.1, 25.8, 25.7, 18.0, 14.1; HRMS (ESI) calcd. for $\text{C}_{26}\text{H}_{29}\text{N}_3\text{O}$ $[M + H]^+$: 400.2383. Found: 400.2388.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-Aminopropyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (5b). The procedure for **1** was followed using 40 mg (0.078 mmol) of **20b**

and 1 mL of 4 M HCl in dioxane to give 37 mg (98%) of **5b** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CD_3OD) δ 8.70–8.58 (m, 1H), 8.40–8.28 (m, 1H), 7.85–7.40 (m, 8H), 7.30–7.20 (m, 2H), 4.42–4.26 (m, 0.5H), 4.25–4.10 (m, 0.5H), 3.95–3.82 (m, 0.5H), 3.78–3.48 (m, 1.5H), 3.10–2.90 (m, 1H), 2.62 (t, J = 7.5 Hz, 2H), 2.22–2.06 (m, 1H), 2.05–1.85 (m, 1H), 1.78–1.68 (m, 3H), 1.42–1.20 (m, 3H), 0.95 (t, J = 6.0 Hz, 3H); HRMS (ESI) calcd. for $\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}$ $[M + H]^+$: 414.2540. Found: 414.2547.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-Amino-3-methylbutyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (5c). The procedure for **1** was followed using 60 mg (0.11 mmol) of **19c** and 1 mL of 4 M HCl in dioxane to give 54 mg (95%) of **5c** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CD_3OD) δ 8.55–8.38 (m, 1H), 8.22–8.10 (m, 1H), 7.70–7.30 (m, 8H), 7.25–7.10 (m, 2H), 4.38–4.25 (m, 0.5H), 4.24–4.10 (m, 0.5H), 3.88–3.40 (m, 2H), 3.30–3.10 (m, 1H), 2.98–2.80 (m, 1H), 2.52 (t, J = 7.5 Hz, 2H), 2.16–1.78 (m, 3H), 1.68–1.46 (m, 2H), 1.00–0.75 (m, 9H); HRMS (ESI) calcd. for $\text{C}_{29}\text{H}_{33}\text{N}_3\text{O}$ $[M + H]^+$: 442.2853. Found: 442.2856.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-Amino-4-methylpentyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (5d). The procedure for **1** was followed using 50 mg (0.09 mmol) of **19d** and 1 mL of 4 M HCl in dioxane to give 46 mg (97%) of **5d** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CD_3OD) δ 8.60–8.50 (m, 1H), 8.30–8.18 (m, 1H), 7.78–7.40 (m, 8H), 7.27 (d, J = 9.0 Hz, 2H), 4.36–4.20 (m, 0.5H), 4.20–4.18 (m, 0.5H), 4.05–3.90 (m, 0.5H), 3.88–3.60 (m, 1.5H), 3.52–3.40 (m, 1H), 3.10–2.90 (m, 1H), 2.62 (t, J = 7.5 Hz, 2H), 2.22–2.08 (m, 1H), 2.00–1.88 (m, 1H), 1.76–1.42 (m, 5H), 1.02–0.75 (m, 9H); HRMS (ESI) calcd. for $\text{C}_{30}\text{H}_{37}\text{N}_3\text{O}$ $[M + H]^+$: 456.3009. Found: 456.3017.

(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-Amino-3-phenylpropyl-(4'-propylbiphenyl-4-yl)amide Dihydrochloride (5e). The procedure for **1** was followed using 70 mg (0.12 mmol) of **20e** and 1 mL of 4 M HCl in dioxane to give 65 mg (96%) of **5e** as a 1:1 diastereomeric mixture: ^1H NMR (300 MHz; CD_3OD) δ 8.65–8.58 (m, 1H), 8.40–8.26 (m, 1H), 7.82–7.70 (m, 1H), 7.70–7.36 (m, 7H), 7.35–7.05 (m, 7H), 4.45–4.30 (m, 0.5H), 4.25–4.10 (m, 0.5H), 4.00–3.86 (m, 0.5H), 3.85–3.55 (m, 1.5H), 3.16–2.88 (m, 3H), 2.69 (t, J = 7.5 Hz, 2H), 2.22–2.05 (m, 1H), 2.05–1.88 (m, 1H), 1.76–1.58 (m, 3H), 0.95 (t, J = 7.5 Hz, 3H); HRMS (ESI) calcd. for $\text{C}_{33}\text{H}_{35}\text{N}_3\text{O}$ $[M + H]^+$: 490.2853. Found: 490.2859.

tert-Butyl [(2S,3S)-1-(4-Bromophenyl)-[(1R,2R)-2-phenyl-1-cyclopropanecarbonyl]amino]-3-methylpentan-2-yl]carbamate (21a). A solution of (1R,2R)-2-phenyl-1-cyclopropanecarboxylic acid¹² (97 mg, 0.6 mmol) in thionyl chloride (3 mL) was refluxed overnight. After cooling to room temperature, the mixture was concentrated under reduced pressure. The resulting residue was dissolved in CH_2Cl_2 (5 mL) and treated with **13** (150 mg, 0.4 mmol) and Et_3N (0.17 mL, 1.2 mmol). The reaction mixture was stirred at room temperature overnight. Saturated NaHCO_3 (5 mL) was added and the layers were separated. The aqueous layer was extracted with CH_2Cl_2 (3 \times 10 mL). The combined organic layers were washed with brine (3 \times 10 mL), dried (Na_2SO_4), and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–25% EtOAc in hexanes afforded **21a** (155 mg, 75%) as a white foam: $[\alpha]_D^{25} +35.2^\circ$ (c 0.52, CH_3OH); ^1H NMR (300 MHz; CDCl_3) δ 7.49 (d, J = 9.0 Hz, 2H), 7.25–7.10 (m, 5H), 6.94 (d, J = 9.0 Hz, 2H), 4.96 (d, J = 12.0 Hz, 1H), 4.37 (dd, J = 12.0, 10.5 Hz, 1H), 3.80–3.66 (m, 1H), 3.13 (dd, J = 12.0, 3.0 Hz, 1H), 2.66–2.55 (m, 1H), 1.61–1.48 (m, 4H), 1.45 (s, 9H), 1.16–1.10 (m, 2H), 0.91–0.82 (m, 6H); ^{13}C NMR (75 MHz; CDCl_3) δ 173.3, 156.4, 141.4, 140.4, 133.1, 130.2, 128.5, 126.4, 122.0, 79.0, 54.1, 50.3, 38.3, 28.6, 26.4, 25.4, 24.1, 17.8, 15.3, 11.9; MS (ESI) m/z 515.4 $[M + H]^+$ (^{79}Br), 517.4 $[M + H]^+$ (^{81}Br).

tert-Butyl [(2S,3S)-1-(4-Bromophenyl)-[(pyridin-2-yl)-methylcarbonyl]amino]-3-methylpentan-2-yl]carbamate (21b). To a solution of **13** (200 mg, 0.54 mmol) in CH_3CN (10 mL) at room temperature were added 2-pyridylacetic acid hydrochloride (113 mg, 0.65 mmol), Et_3N (0.23 mL, 1.6 mmol), and HBTU (246 mg, 0.65 mmol). The reaction mixture was stirred at room temperature overnight. The solution was diluted with EtOAc (50 mL) and washed with saturated NaHCO_3 (10 mL) and brine (10 mL). The organic

phase was dried (Na_2SO_4) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0–25% EtOAc in hexanes afforded **21b** (170 mg, 64%) as a brown residue: ^1H NMR (300 MHz; CDCl_3) δ 8.40 (d, J = 3.0 Hz, 1H), 7.56–7.48 (m, 1H), 7.47 (d, J = 9.0 Hz, 2H), 7.13–6.98 (m, 4H), 4.89 (d, J = 9.0 Hz, 1H), 4.30 (t, J = 12.0 Hz, 1H), 3.70–3.55 (m, 1H), 3.54 (s, 2H), 3.06 (dd, J = 15.0, 3.0 Hz, 1H), 1.50–1.42 (m, 2H), 1.41 (s, 9H), 1.10–0.92 (m, 1H), 0.83–0.70 (m, 6H); ^{13}C NMR (75 MHz; CDCl_3) δ 169.9, 155.1, 154.5, 148.3, 140.1, 135.3, 132.0, 129.2, 122.8, 121.3, 120.7, 77.9, 52.5, 49.0, 42.9, 37.0, 27.4, 24.2, 14.0, 10.7; MS (ESI) m/z 490.8 $[\text{M} + \text{H}]^+$ (^{79}Br), 492.6 $[\text{M} + \text{H}]^+$ (^{81}Br).

tert-Butyl [(2S,3S)-1-[(4'-Propylbiphenyl-4-yl)-[(1R,2R)-2-phenyl-1-cyclopropanecarbonyl]amino]-3-methylpentan-2-yl]carbamate (22a). The procedure for **15a** was followed using 100 mg (0.19 mmol) of **21a** and 54 mg (0.32 mmol) of 4-propylphenylboronic acid to give 80 mg (76%) of **22a** as a white foam: $[\alpha]_D^{23} +71.4^\circ$ (c 0.52, CH_3OH); ^1H NMR (300 MHz; CDCl_3) δ 7.56 (d, J = 9.0 Hz, 2H), 7.48 (d, J = 9.0 Hz, 2H), 7.36–7.22 (m, 4H), 7.21–7.01 (m, 3H), 6.94 (d, J = 9.0 Hz, 2H), 5.08 (d, J = 12.0 Hz, 1H), 4.43 (t, J = 12.0 Hz, 1H), 3.86–3.72 (m, 1H), 3.19 (dd, J = 13.5, 4.5 Hz, 1H), 2.70–2.56 (m, 3H), 1.76–1.55 (m, 6H), 1.47 (s, 9H), 1.18–1.04 (m, 2H), 1.00 (t, J = 7.5 Hz, 3H), 0.93–0.82 (m, 6H); ^{13}C NMR (75 MHz; CDCl_3) δ 173.5, 156.4, 142.3, 141.0, 140.7, 140.5, 137.3, 129.0, 128.6, 128.3, 128.1, 126.9, 126.4, 126.2, 78.7, 54.1, 50.0, 38.2, 37.7, 28.5, 26.1, 25.3, 24.5, 23.9, 17.6, 15.1, 13.8, 11.8; MS (ESI) m/z 555.8 $[\text{M} + \text{H}]^+$.

tert-Butyl [(2S,3S)-1-[(4'-Propylbiphenyl-4-yl)-[(pyridin-2-yl)-methylcarbonyl]amino]-3-methylpentan-2-yl]carbamate (22b). The procedure for **15a** was followed using 170 mg (0.35 mmol) of **21b** and 96 mg (0.54 mmol) of 4-propylphenylboronic acid to give 101 mg (55%) of **22b** as an oil: ^1H NMR (300 MHz; CDCl_3) δ 8.47 (d, J = 3.0 Hz, 1H), 7.65–7.56 (m, 3H), 7.50 (d, J = 9.0 Hz, 2H), 7.42–7.08 (m, 6H), 5.08 (d, J = 9.0 Hz, 1H), 4.44 (t, J = 12.0 Hz, 1H), 3.86–3.74 (m, 1H), 3.69 (s, 2H), 3.08 (dd, J = 15.0, 3.0 Hz, 1H), 2.63 (t, J = 7.5 Hz, 2H), 1.76–1.65 (m, 2H), 1.64–1.47 (m, 2H), 1.45 (s, 9H), 1.16–1.02 (m, 1H), 0.97 (t, J = 7.5 Hz, 3H), 0.92–0.78 (m, 6H); ^{13}C NMR (75 MHz; CDCl_3) δ 171.3, 156.2, 155.9, 149.2, 142.4, 141.2, 140.9, 137.3, 130.2, 129.0, 128.7, 128.3, 126.9, 123.9, 121.6, 78.8, 53.7, 49.9, 43.9, 38.0, 37.7, 28.5, 25.3, 24.5, 15.0, 13.8, 11.8; MS (ESI) m/z 530.9 $[\text{M} + \text{H}]^+$.

(1R,2R)-2-Phenyl-1-cyclopropanecarboxylic Acid [(2S,3S)-2-Amino-3-methylpentyl]-[4'-propylbiphenyl-4-yl]amide Hydrochloride (6a). The procedure for **1** was followed using 60 mg (0.11 mmol) of **22a** and 1 mL of 4 M HCl in dioxane to give 52 mg (96%) of **6a** as a white solid: mp 112°C (fusion); $[\alpha]_D^{23} -5.7^\circ$ (c 0.53, CH_3OH); ^1H NMR (300 MHz; CD_3OD) δ 7.65 (br d, J = 6.0 Hz, 2H), 7.56–7.38 (m, 4H), 7.26 (d, J = 9.0 Hz, 2H), 7.20–7.06 (m, 3H), 6.93 (d, J = 9.0 Hz, 2H), 4.38–4.22 (m, 1H), 3.83–3.60 (m, 1H), 3.44–3.33 (m, 1H), 2.64 (d, J = 7.5 Hz, 2H), 2.54–2.42 (m, 1H), 1.85–1.60 (m, 4H), 1.50–1.16 (m, 4H), 1.03–0.93 (m, 6H), 0.87 (t, J = 6.0 Hz, 3H); ^{13}C NMR (75 MHz; CD_3OD) δ 176.0, 143.8, 142.7, 142.0, 141.5, 138.4, 130.3, 129.8, 129.6, 129.5, 128.0, 127.5, 127.2, 57.0, 50.7, 38.7, 37.3, 28.1, 26.5, 26.0, 25.7, 17.9, 14.4, 14.2, 11.9; HRMS (ESI) calcd. for $\text{C}_{31}\text{H}_{38}\text{N}_2\text{O}$ $[\text{M} + \text{H}]^+$: 455.3057. Found: 455.3061.

2-Pyridylacetic Acid [(2S,3S)-2-Amino-3-methylpentyl]-[4'-propylbiphenyl-4-yl]amide Dihydrochloride (6b). The procedure for **1** was followed using 90 mg (0.17 mmol) of **22b** and 2 mL of 4 M HCl in dioxane to give 80 mg (94%) of **6b** as a white foam: ^1H NMR (300 MHz; CD_3OD) δ 8.76 (br d, J = 6.0 Hz, 1H), 8.41 (br t, J = 7.5 Hz, 1H), 7.92–7.50 (m, 8H), 7.30 (d, J = 6.0 Hz, 2H), 4.50–4.38 (m, 1H), 3.75–3.56 (m, 1H), 3.52–3.38 (m, 1H), 2.64 (d, J = 7.5 Hz, 2H), 1.90–1.60 (m, 3H), 1.50–1.15 (m, 2H), 1.02–0.90 (m, 6H), 0.84 (t, J = 6.0 Hz, 3H) (Methylene protons overlapped with methanol solvent peak); ^{13}C NMR (75 MHz; CDCl_3) δ 169.6, 150.2, 146.5, 142.7, 142.2, 141.6, 139.2, 136.8, 129.6, 129.1, 128.9, 126.9, 125.4, 55.2, 48.9, 39.8, 37.7, 35.8, 26.2, 24.4, 14.2, 13.8, 11.4; HRMS (ESI) calcd. for $\text{C}_{28}\text{H}_{35}\text{N}_3\text{O}$ $[\text{M} + \text{H}]^+$: 430.2853. Found: 430.2860.

Pharmacology. *Materials.* Isoproterenol was purchased from Sigma-Aldrich, and cell culture reagents (media, supplements, antibiotics, etc.) were purchased from Fisher Scientific. Human

GPR88 cDNA was purchased from Missouri S&T cDNA Resource Center. The pGloSensor-22F plasmid was purchased from Promega.

Transient Transfection and cAMP Assay. HEK293T cells were transfected with human GPR88 cDNA and pGloSensor-22F overnight and plated in the poly-L-lysine coated 384-well white clear bottom cell culture plates using DMEM supplemented with 1% dialyzed fetal bovine serum at a density of 15,000 cells in 40 μL medium per well. The cell plates were incubated for 6–20 h before being used for assays. To measure receptor mediated $\text{G}\alpha_q$ -activation, culture medium was removed and assay buffer (20 μL per well of 20 mM HEPES, 1 \times HBSS, pH 7.4) was added, followed by addition of 10 μL of test compound solution at serially diluted concentrations for 15 min at room temperature. After addition of 15 μL of Luciferin (4 mM final) and isoproterenol (200 nM final) and incubation for another 15 min, luminescence was read on the TriLux microbeta counter (PerkinElmer). To measure receptor mediated $\text{G}\alpha_q$ -activation, cells were first incubated with test compound for 15 min followed by 15 μL of 4 mM Luciferin for another 15 min, and then luminescence counted as above.

GloSensor cAMP Assay Using Stable GPR88-22F HEK293 Cells. A GPR88-22F stable cell line was created by overexpressing the human GPR88 receptor and the pGloSensor-22F biosensor in HEK293 cells. The day before the assay, GPR88-22F cells were plated into 96-well white-walled assay plates at a density of 40 000 cells per well in culture medium (DMEM-HG supplemented with 10% FBS, 15 mM HEPES, and 100 units of penicillin/streptomycin). The plated cells were incubated overnight at 37°C , 5% CO_2 . The next day, the culture medium was gently removed and 100 μL of equilibration medium was gently added per the manufacturer's instructions (88% CO_2 -independent medium, 10% FBS, 2% GloSensor cAMP reagent). The cells were incubated in the equilibration medium for 2 h at room temperature in the dark. Test compound dilutions were prepared at 11 \times concentration in 1 \times PBS and 10 μL was added to each appropriate well. Following 10 min at room temperature in the dark, 10 μL of 100 nM (final) isoproterenol (prepared at 12 \times concentration in 1 \times PBS) was added to each appropriate well. Following 30 min at room temperature in the dark, luminescence was read on the FlexStation III (1000 ms integration time, Molecular Devices).

Data Analysis. Relative luminescence units (RLU) were recorded and plotted against compound concentration. Data were fit to a three-parameter logistic function to generate EC_{50} values using GraphPad Prism software (San Diego, CA).

■ ASSOCIATED CONTENT

● Supporting Information

Copies of HPLC results of **1–3**, **4a–i**, **5a–e**, **6a**, and **6b**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Telephone: 919 541-6328. Fax: 919 541-8868. E-mail: cjin@rti.org

Funding

We thank the National Institute of Mental Health (NIMH) for supporting the research at Psychoactive Drug Screening Program (PDSP). XPZ is grateful for financial support by NSF (CHE-1152767) and NIH (R01-GM098777).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Dr. Danni Harris for valuable discussions during the course of this work.

■ REFERENCES

- (1) Mizushima, K., Miyamoto, Y., Tsukahara, F., Hirai, M., Sakaki, Y., and Ito, T. (2000) A novel G-protein-coupled receptor gene expressed in striatum. *Genomics* 69, 314–321.
- (2) (a) Ghate, A., Befort, K., Becker, J. A., Filliol, D., Bole-Feysot, C., Demebele, D., Jost, B., Koch, M., and Kieffer, B. L. (2007) Identification of novel striatal genes by expression profiling in adult mouse brain. *Neuroscience* 146, 1182–1192. (b) Massart, R., Guilloux, J. P., Mignon, V., Sokoloff, P., and Diaz, J. (2009) Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. *Eur. J. Neurosci.* 30, 397–414. (c) Van Waes, V., Tseng, K. Y., and Steiner, H. (2011) GPR88 - a putative signaling molecule predominantly expressed in the striatum: Cellular localization and developmental regulation. *Basal Ganglia* 1, 83–89. (d) Becker, J. A., Befort, K., Blad, C., Filliol, D., Ghate, A., Demebele, D., Thibault, C., Koch, M., Muller, J., Lardenois, A., Poch, O., and Kieffer, B. L. (2008) Transcriptome analysis identifies genes with enriched expression in the mouse central extended amygdala. *Neuroscience* 156, 950–965.
- (3) Quintana, A., Sanz, E., Wang, W., Storey, G. P., Guler, A. D., Wanat, M. J., Roller, B. A., La Torre, A., Amieux, P. S., McKnight, G. S., Bamford, N. S., and Palmiter, R. D. (2012) Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors. *Nat. Neurosci.* 15, 1547–1555.
- (4) Logue, S. F., Grauer, S. M., Paulsen, J., Graf, R., Taylor, N., Sung, M. A., Zhang, L., Hughes, Z., Pulito, V. L., Liu, F., Rosenzweig-Lipson, S., Brandon, N. J., Marquis, K. L., Bates, B., and Pausch, M. (2009) The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? *Mol. Cell Neurosci.* 42, 438–447.
- (5) Lovinger, D. M. (2012) New twist on orphan receptor GPR88 function. *Nat. Neurosci.* 15, 1469–1470.
- (6) Matsuoka, T., Tsunoda, M., Sumiyoshi, T., Takasaki, I., Tabuchi, Y., Seo, T., Tanaka, K., Uehara, T., Itoh, H., Suzuki, M., and Kurachi, M. (2008) Effect of MK-801 on gene expressions in the amygdala of rats. *Synapse* 62, 1–7.
- (7) (a) Ogden, C. A., Rich, M. E., Schork, N. J., Paulus, M. P., Geyer, M. A., Lohr, J. B., Kuczenski, R., and Niculescu, A. B. (2004) Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. *Mol. Psychiatry* 9, 1007–1029. (b) Brandish, P. E., Su, M., Holder, D. J., Hodor, P., Szumiloski, J., Kleinhanz, R. R., Forbes, J. E., McWhorter, M. E., Duenwald, S. J., Parrish, M. L., Na, S., Liu, Y., Phillips, R. L., Renger, J. J., Sankaranarayanan, S., Simon, A. J., and Scolnick, E. M. (2005) Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. *Neuron* 45, 861–872.
- (8) Conti, B., Maier, R., Barr, A. M., Morale, M. C., Lu, X., Sanna, P. P., Bilbe, G., Hoyer, D., and Bartfai, T. (2007) Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. *Mol. Psychiatry* 12, 167–189.
- (9) Befort, K., Filliol, D., Ghate, A., Darcq, E., Matifas, A., Muller, J., Lardenois, A., Thibault, C., Demebele, D., Le Merrer, J., Becker, J. A., Poch, O., and Kieffer, B. L. (2008) Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. *Eur. J. Neurosci.* 27, 2973–2984.
- (10) (a) Bi, Y., Dzierba, C. D., Bronson, J. J., Carson, K., Cianchetta, G., Dong, L., Fink, C., Green, M., Kimball, D., Macor, J. E., Kwon, S., Wang, J., Zhang, Y., Zipp, G. Modulators of G protein-coupled receptor 88. U.S. Patent Application 2011/0245264, 2011;. (b) Bi, Y., Dzierba, C. D., Bronson, J. J., Fink, C., Green, M., Kimball, D., Macor, J. E., Kwon, S., Zhang, Y., and Zipp, G. (2011) Modulators of G protein-coupled receptor 88. U.S. Patent Application 2011/0251204. (c) Dzierba, C. D., Hartz, R. A., Bi, Y., Ahuja, V. T., Bronson, J. J., Carson, K., Cianchetta, G., Green, M., Kimball, D., Kimura, S. R., Kwon, S., Macor, J. E., Zhang, Y., and Zipp, G. (2011) Modulators of G protein-coupled receptor 88. U.S. Patent Application 2011/0251196.
- (11) (a) Chen, Y., Fields, K. B., and Zhang, X. P. (2004) Bromoporphyrins as versatile synthons for modular construction of chiral porphyrins: cobalt-catalyzed highly enantioselective and diastereoselective cyclopropanation. *J. Am. Chem. Soc.* 126, 14718–14719. (b) Chen, Y., and Zhang, X. P. (2007) Asymmetric cyclopropanation of styrenes catalyzed by metal complexes of D₂-symmetrical chiral porphyrin: superiority of cobalt over iron. *J. Org. Chem.* 72, 5931–5934. (c) Chen, Y., Ruppel, J. V., and Zhang, X. P. (2007) Cobalt-catalyzed asymmetric cyclopropanation of electron-deficient olefins. *J. Am. Chem. Soc.* 129, 12074–12075. (d) Dzik, W. I., Xu, X., Zhang, X. P., Reek, J. N., and de Bruin, B. (2010) “Carbene radicals” in Co(II)(por)-catalyzed olefin cyclopropanation. *J. Am. Chem. Soc.* 132, 10891–10902. (e) Lu, H., Dzik, W. I., Xu, X., Wojtas, L., de Bruin, B., and Zhang, X. P. (2011) Experimental evidence for cobalt(II)-carbene radicals: key intermediates in cobalt(II)-based metalloradical cyclopropanation. *J. Am. Chem. Soc.* 133, 8518–8521.
- (12) Cheng, K., Lee, Y. S., Rothman, R. B., Dersch, C. M., Bittman, R. W., Jacobson, A. E., and Rice, K. C. (2011) Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ -agonists and potent μ -opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans. *J. Med. Chem.* 54, 957–969.
- (13) (a) Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., Yadav, P. N., Huang, X. P., Feng, B., Jensen, N. H., Che, X., Bai, X., Frye, S. V., Wetsel, W. C., Caron, M. G., Javitch, J. A., Roth, B. L., and Jin, J. (2011) Discovery of β -arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. *Proc. Natl. Acad. Sci. U.S.A.* 108, 18488–18493. (b) Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X. P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., Simeons, F. R., Stojanovski, L., Prat, A., Seidah, N. G., Constam, D. B., Bickerton, G. R., Read, K. D., Wetsel, W. C., Gilbert, I. H., Roth, B. L., and Hopkins, A. L. (2012) Automated design of ligands to polypharmacological profiles. *Nature* 492, 215–220.
- (14) Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors. *Science* 340, 615–619.